267 Outcomes Following Surgery for Pancreatic Neuroendocrine Tumours: A 14-Year Tertiary-Centre Experience

Résumé fourni par la source

Abstract Aim To evaluate survival outcomes and recurrence patterns following curative-intent resection of pancreatic neuroendocrine tumours at a UK tertiary centre, and to identify prognostic clinicopathological factors. Method Patients undergoing curative-intent surgical resection for PNETs between August 2010 and March 2024 were retrospectively reviewed. Data included demographics, histopathology, recurrence, and survival outcomes. Results Eighty-six patients were included, with a median age of 61.5 years (IQR: 50–71) and equal sex distribution. Most tumours were solitary (88.4%), located in the pancreatic tail (57%), with distal pancreatectomy in 75% of cases. Median tumour size was 25 mm (IQR: 13–40). Lymph node metastases were seen in 23.3%, and R0 resection achieved in 67%. Tumours were predominantly WHO grade 1 (65.1%) or grade 2 (26.7%). Postoperative morbidity occurred in 37.2%, and mortality was 15%. Recurrence occurred in 13.95%, mainly as distant metastases (58.3%), with a median interval of 36.3 months. Five-year overall survival (OS) was 83.0%, with median OS and disease-free survival (DFS) of 143.3 and 147.0 months, respectively. Multivariate analysis showed shorter DFS was independently associated with larger tumour size (p = 0.009), higher grade (p = 0.006), male sex (p = 0.039), vascular (p = 0.003) and perineural invasion (p = 0.042), and nodal metastases (p = 0.015). OS was significantly influenced by Charlson Comorbidity Index (p < 0.001) and tumour grade (p = 0.025). Conclusions PNETs have excellent long-term survival following resection. However, adverse pathological features are linked to increased risk of recurrence and poorer prognosis.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.